IDEXX Laboratories expects revenue growth from expanding its diagnostic testing and diagnostic imaging offerings despite continued weakness in patient visits, with an upward revision to its 2026 outlook bringing the focus to sustained monetisation ahead.
Despite sluggish patient visits, IDEXX Laboratories has indicated that it plans to support revenue through continued adoption of veterinary diagnostic services and the expansion of software and diagnostic imaging services. In particular, strengthening its diagnostic testing and diagnostic imaging offerings is expected to increase utilisation per instrument and lift consumables and service revenue across its existing customer base. The upward revision to the 2026 revenue outlook supports this view.
Risk factors include growth in demand for wellness-related testing and adoption of premium panels in an inflationary environment. The balance between business expansion and R&D spending could affect the achievement of margin targets. Over the longer term, expanded diagnostic capabilities are viewed as contributing to revenue stability, but whether operating costs outpace growth will be critical.